Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF 15.50
+0.32 (2.11%)
Oct 2, 2026, 2:40 PM CET
SWX:SANN Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 101.5 | 77.19 | 39.12 | 103.41 | 7.47 | -1.6 | |
Revenue Growth | 107.08% | 97.32% | -62.17% | 1283.84% | - | - |
Cost of Revenue | 59.91 | 62.01 | 15.53 | 3.24 | 3.59 | 3.77 |
Gross Profit | 41.6 | 15.17 | 23.58 | 100.18 | 3.88 | -5.36 |
Selling, General & Admin | 30.23 | 30.77 | 30.5 | 30.97 | 25.42 | 22.06 |
Research & Development | 20.44 | 22.22 | 26.47 | 18.67 | 24.33 | 29.72 |
Other Operating Expenses | -0.34 | -0.2 | -0.23 | -0.62 | -0.1 | -0.25 |
Operating Expenses | 50.33 | 52.79 | 56.73 | 49.02 | 49.65 | 51.53 |
Operating Income | -8.73 | -37.61 | -33.15 | 51.16 | -45.77 | -56.89 |
Interest Expense | -21.32 | -11.56 | -7.78 | -21.31 | -20.19 | -16.42 |
Interest & Investment Income | 0.41 | 0.41 | 0.93 | 0.51 | - | 0 |
Currency Exchange Gain (Loss) | -3.29 | -3.29 | 2.83 | -1.15 | -0.22 | -0.06 |
Other Non Operating Income (Expenses) | 1.04 | 2.9 | -4.52 | 7.51 | -0.35 | 5.22 |
EBT Excluding Unusual Items | -31.89 | -49.15 | -41.69 | 36.71 | -66.53 | -68.16 |
Gain (Loss) on Sale of Investments | - | - | - | 0.68 | - | - |
Gain (Loss) on Sale of Assets | - | - | 0.04 | 17.68 | - | - |
Asset Writedown | - | - | - | - | -6.21 | - |
Other Unusual Items | 0.1 | 0.1 | -0.02 | -0.25 | 2.12 | 13.44 |
Pretax Income | -31.79 | -49.05 | -41.66 | 54.82 | -70.62 | -54.72 |
Income Tax Expense | 0.14 | 0.19 | 0.31 | 0.04 | 0.46 | 0.81 |
Net Income | -31.93 | -49.24 | -41.97 | 54.78 | -71.08 | -55.53 |
Net Income to Common | -31.93 | -49.24 | -41.97 | 54.78 | -71.08 | -55.53 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 13 | 11 | 11 | 6 | 3 |
Shares Outstanding (Diluted) | 14 | 13 | 11 | 11 | 6 | 3 |
Shares Change | 14.02% | 14.29% | 4.24% | 79.29% | 78.31% | 156.61% |
EPS (Basic) | -2.31 | -3.78 | -3.69 | 5.18 | -11.67 | -16.25 |
EPS (Diluted) | -2.31 | -3.78 | -3.69 | 5.01 | -11.67 | -16.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.64 | -34.82 | -35.68 | 47.18 | -29.9 | -37.36 |
Free Cash Flow Per Share | 0.05 | -2.67 | -3.13 | 4.32 | -4.91 | -10.93 |
Gross Margin | 40.98% | 19.66% | 60.29% | 96.87% | 51.93% | - |
Operating Margin | -8.60% | -48.73% | -84.75% | 49.47% | -612.42% | - |
Profit Margin | -31.46% | -63.79% | -107.30% | 52.97% | -951.10% | - |
Free Cash Flow Margin | 0.63% | -45.11% | -91.21% | 45.62% | -400.05% | - |
EBITDA | -3.64 | -32.54 | -27.99 | 53.76 | -42.56 | -53.59 |
EBITDA Margin | -3.58% | -42.15% | -71.56% | 51.99% | - | - |
D&A For EBITDA | 5.1 | 5.08 | 5.16 | 2.6 | 3.21 | 3.3 |
EBIT | -8.73 | -37.61 | -33.15 | 51.16 | -45.77 | -56.89 |
EBIT Margin | -8.60% | -48.73% | -84.75% | 49.47% | - | - |
Effective Tax Rate | - | - | - | 0.07% | - | - |
Revenue as Reported | 101.5 | 77.19 | 39.12 | 103.41 | 7.47 | -1.6 |